| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/20/2000 | WO2000022112A1 Stabilized bioactive peptides and methods of identification, synthesis and use |
| 04/20/2000 | WO2000022103A1 A modified polypeptide with reduced immune response |
| 04/20/2000 | WO2000022102A1 Biologically active substance, raw material and method for producing the same |
| 04/20/2000 | WO2000022098A1 Porcine oocytes with improved developmental competence |
| 04/20/2000 | WO2000022001A2 A potassium channel of the erg family |
| 04/20/2000 | WO2000021998A1 Bone morphogenetic protein antagonist based on the mature protein |
| 04/20/2000 | WO2000021996A2 Methods and compositions for inhibiting neoplastic cell growth |
| 04/20/2000 | WO2000021995A1 Treatment of inflammatory disease |
| 04/20/2000 | WO2000021993A1 Human ptd010 gene (tpaaag12) |
| 04/20/2000 | WO2000021988A2 Human ankyrin family protein |
| 04/20/2000 | WO2000021987A2 A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease |
| 04/20/2000 | WO2000021986A2 Matrix-remodeling genes |
| 04/20/2000 | WO2000021981A2 TNFα BINDING PEPTIDES AND THEIR UTILIZATION FOR DETECTING, DEACTIVATING AND/OR REMOVING TNFα FROM BIOLOGICAL FLUIDS |
| 04/20/2000 | WO2000021979A2 Cyclic tetrapeptide and their use as histone deacetylase inhibitor |
| 04/20/2000 | WO2000021978A2 Laminin 5, 13 and 14 and uses thereof |
| 04/20/2000 | WO2000021976A1 Bone morphogenic protein-induced genes and polypeptides, and their use in diagnostic and therapeutic methods |
| 04/20/2000 | WO2000021575A2 Calpain inhibitors and their applications |
| 04/20/2000 | WO2000021574A2 Site-directed dual pegylation of proteins |
| 04/20/2000 | WO2000021572A2 Hydrogels and water soluble polymeric carriers for drug delivery |
| 04/20/2000 | WO2000021569A2 Macromolecular active substance conjugates and a method for the production thereof |
| 04/20/2000 | WO2000021567A1 Ionic molecular conjugates of n-acylated derivatives of poly(2-amino-2-deoxy-d-glucose) and polypeptides |
| 04/20/2000 | WO2000021566A1 Sorbefacients and preparations for percutaneous absorption containing the same |
| 04/20/2000 | WO2000021560A1 Flt4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY |
| 04/20/2000 | WO2000021559A2 Blocking factor b to treat complement-mediated immune disease |
| 04/20/2000 | WO2000021558A1 Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway |
| 04/20/2000 | WO2000021557A1 Delta 6 fatty acid desaturase |
| 04/20/2000 | WO2000021555A1 Contraception through antagonizing wnt; oocyte maturation with wnt polypeptide |
| 04/20/2000 | WO2000021554A1 Preventives or remedies for cachexia |
| 04/20/2000 | WO2000021553A2 Method of regulating smn gene expression |
| 04/20/2000 | WO2000021551A1 Isolated peptides which bind to hla-b35 molecules |
| 04/20/2000 | WO2000021550A2 Methods and compositions for treating neurodegenerative diseases |
| 04/20/2000 | WO2000021549A1 A method of inducing or enhancing chondrogenesis with extracellular matrix containing gdf-5 |
| 04/20/2000 | WO2000021548A2 Angiogenically effective unit dose of fgf and method of administering |
| 04/20/2000 | WO2000021547A2 Utilization of proteolytic enzymes to influence hyperactive t cells |
| 04/20/2000 | WO2000021509A2 Methods of treatment |
| 04/20/2000 | WO2000021506A2 Pharmaceutical composition of glutathione modulators with antimony and/or arsenic for cancer therapy |
| 04/20/2000 | WO2000021366A1 Method for preserving a hemoglobin blood substitute |
| 04/20/2000 | WO2000007616A3 Use of novel agents inducing cell death in synergy with interferons |
| 04/20/2000 | WO2000006775A9 Exon deletion antisense drug design and therapy |
| 04/20/2000 | WO2000006605A9 Heterominibodies |
| 04/20/2000 | WO2000005586A3 Rna helicases modulating translation termination |
| 04/20/2000 | WO2000005245A3 Inhibitors of urokinase and blood vessel formation |
| 04/20/2000 | WO2000004145A3 Myotilin, an actin-organizing protein |
| 04/20/2000 | WO2000004052A3 Soluble derivatives of anti-angiogenic peptides |
| 04/20/2000 | WO2000003685A3 Nitrilase homologs |
| 04/20/2000 | WO2000003004A3 Presenilin 2 specific ribozyme |
| 04/20/2000 | WO2000002580A3 Therapies using hemoproteins |
| 04/20/2000 | WO2000001713A9 Diacylglycerol acyl transferase proteins |
| 04/20/2000 | WO2000001440A3 Methods for treating neurological injuries and disorders |
| 04/20/2000 | WO2000000622A3 Human oxidoreductase proteins |
| 04/20/2000 | WO1999067407A3 Transgenetic non-human animal which comprises an inactive peg3 gene, and the use thereof |
| 04/20/2000 | WO1999066065A3 Proteasomal activity |
| 04/20/2000 | WO1999066037A3 Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
| 04/20/2000 | WO1999065712A3 Glycosulfopeptides and methods of synthesis and use thereof |
| 04/20/2000 | WO1999065450A3 Immunosuppressive agents that inhibit calcineurin function and uses thereof |
| 04/20/2000 | WO1999064461A3 Monoclonal antibodies, cross-reactive antibodies and method for producing the same |
| 04/20/2000 | WO1999064046A9 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5-ht3 receptors |
| 04/20/2000 | WO1999064000A9 Novel therapeutic agents that modulate neurokinin receptors |
| 04/20/2000 | WO1999062943A3 Novel molecules of the aip-related protein family and uses thereof |
| 04/20/2000 | WO1999061469A3 Prostate growth-associated membrane proteins |
| 04/20/2000 | WO1999060986A3 Apoptosis modulators that interact with the huntington's disease gene |
| 04/20/2000 | WO1999058658A3 Expression vectors for stimulating an immune response and methods of using the same |
| 04/20/2000 | WO1999057266A3 Immunosuppression by blocking t cell co-stimulation signal 2 (b7/cd28 interaction) |
| 04/20/2000 | WO1999055861A3 Fibroblast growth factor mutein compositions and methods of use therefor |
| 04/20/2000 | WO1999054463A3 Human k+ ion channel and therapeutic applications thereof |
| 04/20/2000 | WO1999053078A3 Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins |
| 04/20/2000 | WO1999053062A3 Isolated sh3 genes associated with myeloproliferative disorders and leukemia, and uses thereof |
| 04/20/2000 | DE19847362A1 New polycyclic aromatic compound-protein conjugates, useful for detection and/or treatment of diseased tissue, e.g. tumors or inflammation sites |
| 04/20/2000 | DE19847114A1 Use of proteolytic enzymes to modulate hyperactive T cells, especially for symptomatic treatment of immune-mediated inflammatory diseases, e.g. multiple sclerosis, diabetes, arthritis or glomerulonephritis |
| 04/20/2000 | DE19847107A1 Use of pertussis toxin to prepare a pharmaceutical composition for treating tumors, especially carcinomas or sarcomas |
| 04/20/2000 | DE19847064A1 Mutant AMPA-type glutamate receptor, useful for identifying receptor agonists and antagonists, lacks the desensitizing properties of the wild-type receptor |
| 04/20/2000 | DE19845405A1 Arylsubstituierte Propanolaminderivate und deren Verwendung Aryl-substituted Propanolaminderivate and their use |
| 04/20/2000 | CA2347968A1 Follistatin-related protein zfsta2 |
| 04/20/2000 | CA2347653A1 Novel cell signaling polypeptides and nucleic acids |
| 04/20/2000 | CA2347121A1 (mbp1) polypeptides capable of interacting with oncogenic mutants of the p53 protein |
| 04/20/2000 | CA2347113A1 Human ankyrin family protein |
| 04/20/2000 | CA2346943A1 Cyclic tetrapeptide compound and use thereof |
| 04/20/2000 | CA2346929A1 A modified polypeptide with reduced immune response |
| 04/20/2000 | CA2346776A1 Non-desensitizing ampa-receptors |
| 04/20/2000 | CA2346775A1 Protein kinase homologs |
| 04/20/2000 | CA2346713A1 Neisseria genomic sequences and methods of their use |
| 04/20/2000 | CA2346466A1 Method for preserving a hemoglobin blood substitute |
| 04/20/2000 | CA2346329A1 Hydrogels and water soluble polymeric carriers for drug delivery |
| 04/20/2000 | CA2346122A1 Stabilized bioactive peptides and methods of identification, synthesis and use |
| 04/20/2000 | CA2346066A1 Ionic molecular conjugates of n-acylated derivatives of poly(2-amino-2-deoxy-d-glucose) and polypeptides |
| 04/20/2000 | CA2346006A1 Delta 6 fatty acid desaturase |
| 04/20/2000 | CA2345885A1 Bone morphogenic protein-induced genes and polypeptides, and their use in diagnostic and therapeutic methods |
| 04/20/2000 | CA2345211A1 Recombinant e1a deleted adenoviral vectors |
| 04/20/2000 | CA2344711A1 Expression and secretion of icil-1 receptor antagonist type ii |
| 04/20/2000 | CA2344465A1 Methods and compositions for inhibiting neoplastic cell growth |
| 04/20/2000 | CA2342314A1 Non-endogenous, constitutively activated human g protein-coupled receptors |
| 04/20/2000 | CA2326675A1 Isolated peptides which bind to hla-b35 molecules |
| 04/20/2000 | CA2314004A1 Matrix-remodeling genes |
| 04/19/2000 | EP0994188A1 Method for obtaining active beta-NGF |
| 04/19/2000 | EP0994187A1 Renin-active substance comprising human prorerin and antibodies to the prorerin profragment |
| 04/19/2000 | EP0993831A2 Compounds and compositions for delivering active agents |
| 04/19/2000 | EP0993613A2 Method for recognizing and determining gnrh receptors and the use of gnrh agonists and gnrh antagonists and other gnrh receptor ligands for the treatment with gnrh receptors of tumours originating in the brain and/or nervous system and/or meninges and/or of kaposi sarcoma |
| 04/19/2000 | EP0993311A2 Compositions containing thrombin and microfibrillar collagen, and methods for preparation and use thereof |
| 04/19/2000 | EP0993305A2 Composition for enhanced uptake of polar drugs from mucosal surfaces |
| 04/19/2000 | EP0993303A1 Substances in order to achieve preference and create acceptance |